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Technical Appendix 1 Figure 1. Map of Liberia counties showing the 25 Ebola virus (EBOV) isolates 
described in this study. Samples were collected from persons in 7 coastal Liberian counties (highlighted 
in green) during September 2014–February 2015. 
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Technical Appendix 1 Figure 2. Mutation analysis of diagnostic binding sites. A single-nucleotide 
polymorphism (SNP) table is combined with a heat map based on 2 categories: 1) mutations shown to be 
tolerated by the therapeutic or diagnostic target (highlighted in green); 2) mutations within the binding 
region of a therapeutic or diagnostic assay that have not yet been tested (highlighted in yellow/orange) 
(20–24,27,30,31); The column designated “% EBOV-WA” stratifies changes by the percentage of 
Western African sequences that support each mutation in comparison with EBOV/Kik-9510621. The 
column designated “% EBOV-LIB” stratifies changes by the percentage of Liberian sequences that 
support each mutation. Changes previously described are highlighted in yellow; changes that appeared 
during circulation in Liberia are highlighted in orange. The reference nucleotide positions reported here 
are in relation to EBOV/Kik (GenBank accession no. AY354458), which is one of the primary isolates 
used as reference for developing these therapeutic drugs and diagnostic assays. The changes to the 
probes are summarized in the Technical Appendix 1 Table. 
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Technical Appendix 1.Diagnostic probe information, used for Figure 2 and Supplementary Figure S4, highlighting mutated probe positions. 
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